Pulmonary Fibrosis

A look back at the breakthroughs in pulmonary fibrosis research, including FDA-approved treatments and innovative diagnostic techniques.

The approval was based on the pivotal phase 3 FIBRONEER-ILD trial, in which nerandomilast slowed lung function decline in PPF and had similar discontinuation rates to placebo.

The 2025 American Thoracic Society International Conference brought advancements in pulmonary medicine and highlighted the need for health equity reforms.

Patients with pulmonary fibrosis (PF) obtain much of their information from the internet, a new report finds, even though a significant amount of information on the internet is incomplete or inaccurate.

Discover key insights from the ERS Congress 2025, highlighting advancements in pulmonary fibrosis treatment and the promising role of nerandomilast.

Common and rare genetic variants linked to idiopathic pulmonary fibrosis (IPF) and reveals substantial genetic overlap with severe COVID-19, highlighting shared biological pathways and potential therapeutic targets.

New research shows patients commonly take lower doses of nintedanib, and the majority are also taking immunomodulatory drugs.

Higher CONUT nutritional scores strongly predict poorer survival and greater lung function decline in PPF, highlighting malnutrition as a key modifiable risk factor.

Combining genetic features with clinical data improved the performance of a pulmonary fibrosis prediction score for people with rheumatoid arthritis.

A study identified 32 dysregulated cytokines and 5 key signaling hubs in idiopathic pulmonary fibrosis (IPF), mapping a complex network of profibrotic pathways that may serve as future therapeutic targets.

A novel RTEL1 nonsense mutation was identified in a woman with multigenerational familial pulmonary fibrosis (PF), expanding the genetic spectrum of telomere-related lung disease and underscoring the importance of genetic testing in suspected inherited interstitial lung disease (ILD).

An RNA-based therapeutic approach led to transient activation of telomerase activity in a model of pulmonary fibrosis.

Nerandomilast slowed disease progression at 2 doses compared with placebo among US participants in the trial.

A national analysis of CDC data over 25 years revealed persistent sex, racial, and regional disparities in pneumonia and pulmonary fibrosis mortality.

Metabolic intermediates were identified as active participants in fibrosis progression and potential targets for next-generation therapies.

Atomic force microscopy successfully identified nanomechanical changes in fibrotic lung tissue.

A Mendelian randomization study suggests Actinomyces plays a role in idiopathic pulmonary fibrosis, mediated by circulating inflammatory proteins.

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment.

A wearable cough monitor generated clinically useful cough data, but patients only wore the device about half of the days of the study period.

A recent study outlines how artificial intelligence advancements are transforming research and therapeutic strategies for idiopathic pulmonary fibrosis.

Patients with progressive pulmonary fibrosis had longer survival with antifibrotic therapy, but only if they met a key criteria.

Patients with acute exacerbations of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis face steep odds and benefit from palliative care.

Findings reveal that alternative polyadenylation regulates SASP factors and may fuel age-related pulmonary fibrosis.

Polyethylene terephthalate microplastics are the most common microplastics encountered in daily life, and there are several reasons why they may play a role in lung diseases like idiopathic pulmonary fibrosis.

While observational studies have previously pointed to an association, being able to identify causation has been difficult due to overlapping risk factors and confounding variables.